{ "week": "2026-W31", "label": "Week 31 \u2014 August 2\u20138, 2026", "week_start": "2026-08-02", "generated": "2026-08-03", "stats": { "total_entries": 964, "new_this_week": 90, "compounds_represented": 7 }, "by_compound": { "psilocybin": [ { "id": "a1e0b6daa6b63cb393b7009eabc60c33f2cf4e4ff433026300598ed4be4e655c", "title": "Psilocybin for Fear of Cancer Recurrence.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-01", "abstract": null, "outcome_summary": null, "doi": "10.1007/s00520-026-11065-3", "url": "https://pubmed.ncbi.nlm.nih.gov/42541603/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for fear of cancer recurrence is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "b67989a0cc4730b3de7d8d8b719d25bcba4b1e2ec0f926a68f087409deff8b63", "title": "Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-09-01", "abstract": "Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to date have studied individual models of psilocybin therapy, but group models may offer increased access and benefits of community.\u2026", "outcome_summary": null, "doi": "10.1177/28314425251404460", "url": "https://pubmed.ncbi.nlm.nih.gov/42539893/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin therapy for cancer-related anxiety and depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "d3124493ddbc28ffac424abe52b0fa0006bec4794f3c80aca5c5aaa1448b7dd1", "title": "A Nature-Themed Video Intervention Increases Nature Relatedness in Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-09-01", "abstract": "Psychedelic-assisted psychotherapy has shown promising results for treating alcohol use disorder (AUD) and other mental health conditions.\u2026", "outcome_summary": null, "doi": "10.1177/28314425251387655", "url": "https://pubmed.ncbi.nlm.nih.gov/42539824/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin-assisted psychotherapy for alcohol use disorder.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "1de8db821a57ee9122383ecc6e7069b564841a96987a2efd3b3d92ac84bb5a08", "title": "Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-09-01", "abstract": "Psilocybin has been granted breakthrough therapy status in the United States, speeding its advancement from research to clinical care. Due to the controversial nature of psilocybin, psychiatrists may not be fully prepared to incorporate it into clinical practice.\u2026", "outcome_summary": null, "doi": "10.1177/28314425251381806", "url": "https://pubmed.ncbi.nlm.nih.gov/42539773/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psychiatrist readiness for psilocybin in clinical practice.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "930d76337e41de76c161b47a2807704d3a9235f3c458935bb941dbad3bb8d86f", "title": "Psilocybin asymmetrically modulates outcome-based choice and cortical processing under uncertainty.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-21", "abstract": "Emerging clinical research with psilocybin highlights the value of the psychedelic experience on successful treatment of a multitude of psychiatric disorders.\u2026", "outcome_summary": null, "doi": "10.64898/2026.07.16.733837", "url": "https://pubmed.ncbi.nlm.nih.gov/42539231/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for psychiatric disorders and choice under uncertainty.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "44909dc9d85ebc6e5c583aeef4335dce0faccfe1f9f32de4cca6fabc441e0d50", "title": "Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-04-01", "abstract": "Psilocybin, a serotonergic psychedelic, has gained attention as a potential treatment for various psychiatric conditions. In this review, the authors summarize current clinical evidence related to psilocybin's efficacy, safety, and mechanisms of action across psychiatric disorders.\u2026", "outcome_summary": null, "doi": "10.1176/appi.focus.20250043", "url": "https://pubmed.ncbi.nlm.nih.gov/42538940/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Review of psilocybin for psychiatric disorders, efficacy, and mechanisms.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "ebd980cbb79293b837b223d01593a7d536b932dcbb80a6a60e22d2c583cba255", "title": "Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-01", "abstract": "Psilocybin-assisted interventions are moving from efficacy trials toward psychiatric implementation.\u2026", "outcome_summary": null, "doi": "10.1007/s00228-026-04151-2", "url": "https://pubmed.ncbi.nlm.nih.gov/42538465/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Review of psilocybin safety in psychiatric practice.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "8dc733ea098d802d3c21154eaca73f31cabbef17d2a087ff1b75b6856ff08b2f", "title": "Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe,\u00a0treatment-resistant PTSD: an open-label pilot clinical trial.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "PTSD", "sample_size": null, "status": "published", "date": "2026-07-30", "abstract": "Psilocybin-assisted therapy (PAT) shows promise for treating PTSD in adults but hasn't been studied in U.S. military Veterans, who face higher symptom severity and suicide risk. This open-label pilot trial evaluated the safety and feasibility of PAT in Veterans with severe, treatment-resistant PTSD.\u2026", "outcome_summary": null, "doi": "10.1038/s43856-026-01767-4", "url": "https://pubmed.ncbi.nlm.nih.gov/42533157/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD in veterans", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "e16a06981da23a9bbfbf0be1411fe9996dc1331ddff1fe5a82aa4694685fdfbb", "title": "Psilocybin-Assisted Early Palliative Care for Demoralization and Chronic Pain: An Open-Label Pilot Study.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-14", "abstract": "Demoralization, a syndrome of helplessness, hopelessness, and loss of meaning and chronic pain are common sources of distress in early palliative care. Psilocybin-assisted therapy (PAT) is an emerging intervention with preliminary data suggesting improvements in pain and demoralization.\u2026", "outcome_summary": null, "doi": "10.64898/2026.07.11.26357570", "url": "https://pubmed.ncbi.nlm.nih.gov/42528601/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for demoralization and chronic pain in palliative care.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "bf349b14543fa5de8126f4b475f2c2402261b2a69531592aa626cd70106f0984", "title": "Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-28", "abstract": "Despite distinct receptor targets, both ketamine and serotonergic psychedelics produce a rapid clinical response and share biological signatures that suggest convergence on common downstream molecular mediators.\u2026", "outcome_summary": null, "doi": "10.1038/s41380-026-03777-z", "url": "https://pubmed.ncbi.nlm.nih.gov/42521762/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "d32677a02825413181f12f112c73d85ecad28d243eb2f1c08f02f7983acf646b", "title": "From trial to clinic: psilocybin's efficacy in routine treatment-resistant depression.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-01", "abstract": null, "outcome_summary": null, "doi": "10.1016/j.lanepe.2026.101780", "url": "https://pubmed.ncbi.nlm.nih.gov/42519708/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "6690f2b10975d2849e471d3d80597c3eb1ca783fd909e1bea396adc5ed684893", "title": "Candidate Biomarkers of Bipolar Disorder Progression: Implications for Ketamine and Psychedelic Interventions.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-28", "abstract": "Bipolar depression is the main driver of disability, suicidality, and treatment resistance in bipolar disorder (BD). The neuroprogression hypothesis proposes that repeated mood episodes and related biological disturbances contribute to worsening outcomes over time.\u2026", "outcome_summary": null, "doi": "10.1007/s12035-026-06086-2", "url": "https://pubmed.ncbi.nlm.nih.gov/42517990/", "source": "PubMed", "first_seen": "2026-08-03" }, { "id": "4c0a408e58fa29aa950520d03177cc5a164a19fff08f6d2a4790eb27a6f8aad1", "title": "Participants' Music Experiences Associated With Psychedelic-Assisted Psychotherapy for Life-Threatening Illness: Interpretivist Research.", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-24", "abstract": "Limited evidence supports treatment for distress in life-threatening illness. Psychedelic-assisted psychotherapy (PAP) may help. Despite music's presence in PAP, sparse accounts of music-related experiences exist. Such research is needed to optimize music's presence within PAP.\u2026", "outcome_summary": null, "doi": "10.1093/jmt/thag015", "url": "https://pubmed.ncbi.nlm.nih.gov/42517555/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psychedelic-assisted psychotherapy for distress in life-threatening illness.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "dfa08e7809a6d4a755f8b61f4d63ee42eeaa7612e03593b8f186a455c45d5930", "title": "Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development.", "compound": "psilocybin", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-03", "abstract": "Naturally derived psilocybin is widely used, yet its therapeutic potential, pharmacological distinctiveness and regulatory feasibility remain understudied.\u2026", "outcome_summary": null, "doi": "10.3390/biom16070983", "url": "https://pubmed.ncbi.nlm.nih.gov/42509777/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Framework for psilocybin policy and clinical development.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "3a743292fa0e0154f4bea23e52dac11b394c4f9d5611d2577b98aa43865e1be5", "title": "[Illicit use of classic psychedelics and suicidality: A systematic literature review].", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-07-27", "abstract": "Given the contrasting results available in the literature, the objective of this systematic review was to investigate the specific impact of illicit use of classic psychedelics (psilocybin, LSD, DMT, mescaline) on suicidality (suicidal ideation, suicide planning, suicide attempts, suicides).\u2026", "outcome_summary": null, "doi": "10.1016/j.encep.2026.04.004", "url": "https://pubmed.ncbi.nlm.nih.gov/42509061/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Review of illicit psychedelic use and suicidality in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "3067c2d0f505086407a099b4103564e36f368f6ac7ef969f80fd9ea3d60ce868", "title": "Precision Functional Brain Mapping in Psilocybin", "compound": "psilocybin", "type": "observational", "institution": "Washington University School of Medicine", "condition": "other", "sample_size": 11, "status": "completed", "date": "2021-06-01", "abstract": "This project will employ functional brain imaging to study the mechanism and immediate and long-term effects of psilocybin, a serotonin receptor 2A agonist, on cortical and cortico-subcortical brain networks in healthy adults.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04501653", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Human study on psilocybin's brain effects and mechanism.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "59771191c82666781b4775f6d43e77e198a74efec981174f415f430200c643b7", "title": "Open-Label Psilocybin Study in Transdiagnostic Population", "compound": "psilocybin", "type": "phase_1", "institution": "Yale University", "condition": "depression", "sample_size": 50, "status": "recruiting", "date": "2024-10-17", "abstract": "The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06442423", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for psychiatric symptoms in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "c3f3b31b0727a9cfd9f241c7ea725e12df0ac19c9b5adb16d3bcadde8c03dec0", "title": "Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans", "compound": "psilocybin", "type": "phase_2", "institution": "Combat Stress", "condition": "PTSD", "sample_size": 8, "status": "active", "date": "2023-06-01", "abstract": "Post-Traumatic Stress Disorder (PTSD) is a mental health condition that occurs as a result of a traumatic experience. Symptoms include feeling anxious, flashbacks, nightmares and difficulty sleeping.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05876481", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD in military veterans is within scope.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "d91792298f5cab4207d6e4005392df6b2b62853e7167614be23c438d6d699609", "title": "Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression", "compound": "psilocybin", "type": "phase_2", "institution": "Central Institute of Mental Health, Mannheim", "condition": "depression", "sample_size": 144, "status": "completed", "date": "2021-06-10", "abstract": "The study aims to investigate the safety and efficacy of oral psilocybin administered under supportive conditions in treatment-resistant major depression (TRD).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04670081", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "4b15bb100f5d3b99947d16ebbbc2e2f4a0eaa5084c26f5fafac95ba569b8eef4", "title": "An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics", "compound": "psilocybin", "type": "phase_1", "institution": "Usona Institute", "condition": "other", "sample_size": 60, "status": "completed", "date": "2022-06-22", "abstract": "This study is comprised of two parts. The purpose of the first part of this study is to evaluate the effects of a supratherapeutic dose of psilocybin on cardiac repolarization. The purpose of the second part of the study is to evaluate the effects of food on the pharmacokinetics of psilocybin.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05478278", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Human study on psilocybin pharmacokinetics and safety.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "169b2499c04d496ec42b2b03769fa4aeb8a618fa0a4cf25e35231028f5818bb5", "title": "Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer", "compound": "psilocybin", "type": "phase_2", "institution": "Sunstone Medical", "condition": "depression", "sample_size": 56, "status": "active", "date": "2023-10-23", "abstract": "This is a Phase 2, single-center study to explore the efficacy, safety, and tolerability of up to two 25-mg doses of psilocybin administered at an interval of 9 to 10 weeks in patients with MDD and cancer.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05947383", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for MDD in cancer patients is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "5f5836855975676c2b717fa0eff26839cf5692cee673c75054dcc651065f5100", "title": "Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder", "compound": "psilocybin", "type": "phase_1", "institution": "Johns Hopkins University", "condition": "PTSD", "sample_size": 0, "status": "completed", "date": "2025-01-01", "abstract": "The purpose of this study is to evaluate the safety, tolerability, and potential efficacy of psilocybin-assisted psychotherapy to reduce post-traumatic stress disorder (PTSD) severity in a sample of individuals with PTSD.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05562973", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for PTSD in humans, evaluating safety and efficacy.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "47f7d1ec9adf365151ff50bff04804309269ff5e671a04a87bb707ffd4f2ba94", "title": "The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder", "compound": "psilocybin", "type": "phase_3", "institution": "Sharmin Ghaznavi", "condition": "depression", "sample_size": 20, "status": "recruiting", "date": "2024-09-10", "abstract": "This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06247839", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for major depressive disorder, fMRI study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "5c990ee1cdf8498c70edb94b356998aedb740bc54cdbf38ad7fd918947eac89b", "title": "Wellcome Leap Psilocybin for OUD", "compound": "psilocybin", "type": "phase_2", "institution": "Anna Rose Childress, Ph.D.", "condition": "addiction", "sample_size": 36, "status": "recruiting", "date": "2025-10-07", "abstract": "Investigators will recruit 36 individuals on MAT for OUD for a double-blind, placebo-controlled design to determine whether PEX010 (25-mg/d) shows preliminary efficacy on neural correlates of neurocognition and on clinical outcomes.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06786325", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for opioid use disorder (OUD) in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "e633b408384ee15cd5594f206ff7b631c65d635704b2113da2119d33f94336a7", "title": "The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder", "compound": "psilocybin", "type": "phase_2", "institution": "COMPASS Pathways", "condition": "PTSD", "sample_size": 22, "status": "completed", "date": "2022-06-10", "abstract": "The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05312151", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin (COMP360) for PTSD is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "d85effce0a2f6b13da96fa7cbb58724308930b6f59b34e252fc2706f88ed0367", "title": "Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": null, "status": "active", "date": "2026-02-16", "abstract": "Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD).\u2026", "outcome_summary": "Compass Pathways will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic formulation of psilocybin, for treatment-resistant depression. Data from Part A and Part B of COMP005 and Part A of COMP006 will be disclosed.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-to-Announce-New-Clinical-Data-from-Two-Ongoing-Phase-3-Trials/default.aspx", "source": "Compass Pathways", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression, Phase 3 trials.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "5c056c5eefad64188b8b49bed89cddff4536d1803516270b709be97934d03103", "title": "Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": 258, "status": "active", "date": "2025-04-22", "abstract": "These risks, uncertainties, and other factors include, among others: uncertainties associated with risks related to clinical development which is a lengthy and expensive process with uncertain outcomes, and therefore our clinical trials may be delayed or terminated and may be more costly than expected; the results of early-stage clinical trials of our investigational COMP360 psilocybin treatment may not be predictive of the results of later stage clinical trials; our need for substantial [...] and clinical sites that are making this study possible.\u2026", "outcome_summary": "Dosing is complete for all participants in Part A of the COMP005 phase 3 trial for treatment resistant depression. Top-line 6-week primary endpoint results are expected in late June.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Dosing-Complete-for-All-Participants-in-Part-A-of-Phase-3-COMP005-Trial-of-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx", "source": "Compass Pathways", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Phase 3 trial of psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "e1475594c69c1387d99aec384e0778c522b6c26688e160ea1f1d9f02c6206877", "title": "Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways plc", "condition": "depression", "sample_size": null, "status": "recruiting", "date": "2023-11-15", "abstract": "The ongoing phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted and follows promising results from Compass\u2019s phase 2b study of COMP360 psilocybin treatment.\u2026", "outcome_summary": "Compass Pathways has initiated the UK component of its global phase 3 program for COMP360 psilocybin treatment in treatment-resistant depression. The program includes two pivotal trials, COMP 005 and COMP 006, with COMP 006 taking place in the UK and globally, studying three dose arms of COMP360.", "doi": null, "url": "https://ir.compasspathways.com/News--Events-/news/news-details/2023/Compass-Pathways-initiates-UK-component-of-global-phase-3-study-of-psilocybin-treatment-in-treatment-resistant-depression-and-launches-new-research-center/default.aspx", "source": "Compass Pathways", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Phase 3 study of psilocybin for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "196e6f90c0acbde7abceed9817ae5c1398398641f7bd10a2f4bab2060cfc5988", "title": "For veterans with severe PTSD, psilocybin-assisted therapy may help", "compound": "psilocybin", "type": "phase_2", "institution": "The Ohio State University", "condition": "PTSD", "sample_size": 12, "status": "published", "date": "2026-07-31", "abstract": "But the preliminary clinical results exceeded researchers\u2019 expectations: In the pilot trial with 12 veterans, 75% of participants were in remission one month after the study\u2019s end. Their symptoms no longer met the criteria for post-traumatic stress disorder.\u2026", "outcome_summary": "A pilot clinical trial with 12 veterans found that 75% were in remission from PTSD one month after psilocybin-assisted therapy. The treatment was safe, with no serious adverse events or increases in suicidal thinking.", "doi": "s43856-026-01767-4", "url": "https://news.osu.edu/for-veterans-with-severe-ptsd-psilocybin-assisted-therapy-may-help", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin-assisted therapy for PTSD in veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "983700ba2a6d2f02c23e9a672cf30f740ee9e528b3403220e969c6add0c696eb", "title": "Phase 3 Program Investigating COMP360 Psilocybin for Treatment-Resistant Depression: Breaking Poster Data from the 2026 ASCP Annual Meeting", "compound": "psilocybin", "type": "phase_3", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-05-28", "abstract": "Low prior classic psychedelic exposure (~5%) reduced under-blinding and minimized psychedelic-seeking enrollment, enhancing internal validity and clinical-practice representativeness.\u2026", "outcome_summary": "Poster data from the 2026 ASCP Annual Meeting is presented regarding the Phase 3 program investigating COMP360 psilocybin for treatment-resistant depression.", "doi": null, "url": "https://www.psychiatrictimes.com/view/phase-3-program-investigating-comp360-psilocybin-for-treatment-resistant-depression-breaking-poster-data-from-the-2026-ascp-annual-meeting", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression, human study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "2fed19a257a9d32be811b22972baae80494dc40f86a2ab320c5ff7cfb75dcd97", "title": "Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial", "compound": "psilocybin", "type": "phase_2", "institution": null, "condition": "suicidal_ideation", "sample_size": 20, "status": "completed", "date": "2026-05-13", "abstract": "Published Online: May 13, 2026. \u00a9 2026 Physicians Postgraduate Press, Inc. Submitted: January 22, 2026; accepted March 13, 2026. To Cite: van der Vaart A, LaPratt J, Swartz K, et al. Efficacy and safety of a single dose of psilocybin for chronic suicidal ideation: an open-label trial.\u2026", "outcome_summary": "This open-label, single-arm study evaluated a single 25-mg dose of psilocybin with psychological support in 20 adults with chronic suicidal ideation and treatment-resistant depression. The primary outcome was the change from baseline in the Modified Scale for Suicidal Ideation (MSSI) at week 3.", "doi": "26m16338", "url": "https://www.psychiatrist.com/jcp/efficacy-safety-single-dose-psilocybin-chronic-suicidal-ideation-open-label-trial", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for chronic suicidal ideation and depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "611284818b35ef5509cf264374a5d01d62e30eea0ed0e0bffdb1afceb576e847", "title": "Psilocybin Failed to Live Up to Hype for Treatment-Resistant Depression", "compound": "psilocybin", "type": "phase_2", "institution": "Heidelberg University", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-03-18", "abstract": "Medical News # Psilocybin Failed to Live Up to Hype for Treatment-Resistant Depression \u2014 Researchers questioned psychedelic's true efficacy in unblinded trials March 18, 2026 \u2022 4 min read A photo of a man holding a psilocybin mushroom. A photo of a man holding a psilocybin mushroom.\u2026", "outcome_summary": "The phase IIb EPISODE trial found that psilocybin plus psychotherapy showed limited efficacy for easing depressive symptoms in individuals with treatment-resistant depression. While secondary outcomes showed some improvement, the primary outcome was not statistically significant, leading to inconclusive findings.", "doi": "10.1001/jamapsychiatry.2026.0132", "url": "https://www.medpagetoday.com/psychiatry/depression/120375", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for treatment-resistant depression study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "4ecb1204c5ccafe3c40662fef2feb5516d15d4ee392022303cf7af093744c1f3", "title": "Compass says its psilocybin drug helped patients with severe depression in two trials", "compound": "psilocybin", "type": "phase_3", "institution": "Compass Pathways", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-02-17", "abstract": "## Results support FDA approval, but it\u2019s unclear how competitive the treatment will be Manage alerts for this article Email this article Share this article Jenny Kane/AP By Elaine Chen Feb.\u2026", "outcome_summary": "Compass Pathways' COMP360 psilocybin therapy showed positive results in two Phase 3 trials for severe depression, meeting primary endpoints and demonstrating significant reductions in depressive symptoms. The company plans to submit these findings to regulatory authorities.", "doi": null, "url": "https://www.statnews.com/2026/02/17/compass-pathways-comp360-psilocybin-severe-depression-trial-results", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin therapy for severe depression in human trials.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "ba0912f88b07da2553a8aad2f6700797c9782e442ed0a752dda3577c9728f2d1", "title": "OHSU-led research initiative examines supervised psilocybin", "compound": "psilocybin", "type": "observational", "institution": "Oregon Health & Science University", "condition": "other", "sample_size": null, "status": "active", "date": "2026-02-12", "abstract": "# News Text Size A A A Share twitter Tweet Share Email Print # OHSU-led research initiative examines supervised psilocybin Five-year, $3.3 million award is first to study the effect of psychedelic services in community settings By Erik Robinson February 12, 2026 Portland, OR Lea esta p\u00e1gina en espa\u00f1ol psilocybin\") [...] Public interest has been fueled by promising results in recent years from early clinical trials in depression, anxiety and post-traumatic stress disorder.\u2026", "outcome_summary": "A five-year, $3.3 million federally funded research initiative led by OHSU will assess the safety and effectiveness of state-regulated psilocybin services in community settings, aiming to inform other states considering similar legal frameworks.", "doi": null, "url": "https://news.ohsu.edu/2026/02/12/ohsu-led-research-initiative-examines-supervised-psilocybin", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psilocybin for therapeutic use in humans, regulatory context.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "03b0fa081554c3ba464defcb7e38e00b95a947d770bf13e493b489c0a76e16be", "title": "Connecticut moves to expand psychedelic-assisted therapy study for PTSD, depression", "compound": "psilocybin", "type": "observational", "institution": "State of Connecticut", "condition": "PTSD", "sample_size": null, "status": "active", "date": "2026-05-07", "abstract": "# Connecticut moves to expand psychedelic-assisted therapy study for PTSD, depression. HARTFORD \u2014 State legislators sent Gov.\u2026", "outcome_summary": "Connecticut is expanding a pilot program for psychedelic-assisted therapy using MDMA or psilocybin for PTSD and depression. The program, initially limited to veterans and first responders, will now be open to qualifying patients 18 and older. The legislation also removes a sunset clause, allowing the program to continue even if MDMA and psilocybin are approved for medical use by the DEA.", "doi": null, "url": "https://www.greenwichtime.com/politics/article/ct-psychedelics-therapy-pilot-program-expand-bill-22245910.php", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psychedelic therapy for PTSD and depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } } ], "mdma": [ { "id": "dc8d079c8858806e157a6793cb72f1eb073eaf82bb3a1290a4cdb11d59386ffd", "title": "Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)", "compound": "mdma", "type": "phase_1", "institution": "University Hospital, Basel, Switzerland", "condition": "other", "sample_size": 16, "status": "completed", "date": "2001-06-01", "abstract": "MDMA (3,4-Methylenedioxymethamphetamine, \"Ecstasy\") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. Ecstasy use has also been associated with rare cardio- and cerebrovascular complications.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT00895804", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "MDMA interaction study in humans", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "da400b627f5d647d623a6b134840f4fa13e01f4399866a0e749adc46266583bc", "title": "Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)", "compound": "mdma", "type": "phase_1", "institution": "University Hospital, Basel, Switzerland", "condition": "other", "sample_size": 16, "status": "completed", "date": "2009-04-01", "abstract": "MDMA releases dopamine, serotonin, and norepinephrine in the brain. Serotonin uptake inhibitors have been shown to interact with 3,4-Methylenedioxymethamphetamine (MDMA) and to decrease its psychoactive and cardiovascular stimulant effects.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT00886886", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Human study on MDMA pharmacodynamics and pharmacokinetics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "b3af074d406250aa4c59ada7d8a6d1c4d6a5dcef23625fa8943110c6958fd9bf", "title": "New VA Trial of MDMA Psychedelic for PTSD: What Veterans Need to Know", "compound": "mdma", "type": "phase_2", "institution": "Department of Veterans Affairs", "condition": "PTSD", "sample_size": 80, "status": "recruiting", "date": "2026-07-01", "abstract": "# New VA Trial of MDMA Psychedelic for PTSD: What Veterans Need to Know. The trial is real, and it is a meaningful step. The Department of Veterans Affairs began enrolling veterans in its first-ever clinical trial of therapy assisted by MDMA, or Ecstasy, in May 2026. ## What the VA\u2019s MDMA Trial Is.\u2026", "outcome_summary": "The VA began enrolling veterans in its first-ever clinical trial of therapy assisted by MDMA for treatment-resistant PTSD and alcohol use disorder in May 2026. Approximately 80 veterans will be enrolled in this randomized, placebo-controlled, double-blind study, with results expected in May 2030.", "doi": null, "url": "https://www.military.com/health-wellness/veterans-health-care/new-va-trial-of-mdma-psychedelic-for-ptsd-what-veterans-need-to-know", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "MDMA for PTSD in veterans is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "08f3632aaa500c55d127ca1f9dc7dfd8e0ac8f6bc0891eeed4d039079def3f65", "title": "Trump throws support behind psychedelics with executive order", "compound": "mdma", "type": "regulatory", "institution": null, "condition": "PTSD", "sample_size": null, "status": "approved", "date": "2026-04-20", "abstract": "## A new executive order could usher in psychedelics as the \u201ckey next wave\u201d of mental health therapies, according to analysts at RBC Capital Markets.\u2026", "outcome_summary": "President Donald Trump signed an executive order to accelerate the development of and facilitate broader access to psychedelic therapies for serious mental health conditions. The order directs the FDA to grant Commissioner's National Priority Vouchers to appropriate psychedelic drugs with breakthrough designation, potentially shortening review periods.", "doi": null, "url": "https://www.biospace.com/policy/trump-throws-support-behind-psychedelics-with-executive-order", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Regulatory decision and policy news regarding psychedelic therapies.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "ed956fa508d5a66334f10d45407d75debedbacfc02e7bf8f23bbc753b1022bf0", "title": "MDMA Therapy in Australia Shows Results, but the Cost Is Limiting Access", "compound": "mdma", "type": "regulatory", "institution": "Therapeutic Goods Administration", "condition": "PTSD", "sample_size": 200, "status": "active", "date": "2026-03-24", "abstract": "\u201cCompared to conventional treatments, the outcomes we\u2019re seeing to date with MDMA-assisted therapy have been extraordinary,\u201d said Dr. Ranil Gunewardene, a psychiatrist in Sydney who has treated more than 40 patients since the Australian regulators created a legal pathway for the drug.\u2026", "outcome_summary": "In Australia, MDMA-assisted therapy for PTSD has shown striking early results, with over half of patients reporting significant relief and no serious adverse events recorded among nearly 200 participants. However, the high cost and limited access pose significant barriers to widespread adoption.", "doi": null, "url": "https://www.nytimes.com/2026/03/24/health/mdma-therapy-ptsd-psychedelic-australia.html", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "MDMA-assisted therapy for PTSD in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "f55b85a91e021ad77f4087712fa94dbff716df299f7a849ec5628449e02762b8", "title": "FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future \u2018Real-Time\u2019 Access", "compound": "mdma", "type": "news", "institution": "FDA", "condition": "PTSD", "sample_size": null, "status": "approved", "date": "2025-09-04", "abstract": "# FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future \u2018Real-Time\u2019 Access ## Perhaps the most interesting of the pile of FDA rejection letters was for Lykos Therapeutics\u2019 MDMA therapy.\u2026", "outcome_summary": "The FDA released a cache of rejection letters, including one for Lykos Therapeutics' MDMA therapy for PTSD. The agency also announced plans to make future complete response letters publicly available in real-time after issuance.", "doi": null, "url": "https://www.biospace.com/policy/fda-drops-another-cache-of-heavily-redacted-rejection-letters-promises-future-real-time-access", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "FDA decision on MDMA therapy for PTSD", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "ceccc51463691cdbb8fb05dce94c1a5f71579365033fb9696a024ddd7ed11dd6", "title": "VA Launches MDMA Clinical Trial to Measure Effects on PTSD, Mental Health", "compound": "mdma", "type": "phase_3", "institution": "Department of Veterans Affairs (VA)", "condition": "PTSD", "sample_size": 80, "status": "recruiting", "date": "2026-05-26", "abstract": "The Department of Veterans Affairs (VA) on Tuesday announced a new clinical trial of methylenedioxymethamphetamine-assisted therapy, more commonly known as MDMA, to evaluate the safety and efficacy when treating current and former military personnel for severe mental health disorders including posttraumatic stress disorder (PTSD) and alcohol use disorder.\u2026", "outcome_summary": "The VA is launching a randomized controlled trial to evaluate the safety and efficacy of MDMA-assisted therapy for PTSD and alcohol use disorder in approximately 80 veterans. Results will compare outcomes between those receiving MDMA-assisted therapy and those receiving psychotherapy with an active placebo.", "doi": null, "url": "https://www.military.com/va-launches-mdma-clinical-trial-to-measure-effects-on-ptsd-mental-health", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "MDMA for PTSD in veterans, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } } ], "ketamine": [ { "id": "c3f536f85a07b2af26774021c5e58ea62033d730def1874b9a6cf4e4dcfad4dd", "title": "Ketamine for substance use disorders: a systematic review and meta-analysis.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "addiction", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Substance use disorder (SUD) is a major global health issue, contributing significantly to the disease burden. Despite this, effective treatments for SUD remain limited. Ketamine has shown potential as a treatment, yet no meta-analysis has assessed its efficacy for SUD.\u2026", "outcome_summary": null, "doi": "10.3389/fpsyt.2026.1835709", "url": "https://pubmed.ncbi.nlm.nih.gov/42540381/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for substance use disorders is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "7d393a1107de3c9dabdafd3e24a1009f48a36a41f44adafe743f22de52dc40b4", "title": "Ketamine persists within neuronal compartments long after systemic clearance.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-22", "abstract": "Ketamine produces rapid and sustained antidepressant effects after a single dose. Plasma membrane NMDA receptors are the presumptive primary molecular targets, yet how ketamine distributes, localizes, and engages neurons across cellular and subcellular compartments remains largely unknown.\u2026", "outcome_summary": null, "doi": "10.21203/rs.3.rs-10234621/v1", "url": "https://pubmed.ncbi.nlm.nih.gov/42539064/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine's antidepressant effects and neuronal distribution in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "a155693cfafce9292089b459ea80034c9aca87cf30115e63c7a66b0269fd0b2a", "title": "Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-04-01", "abstract": "To evaluate the efficacy, safety, and tolerability of esketamine nasal spray vs psychoactive placebo (oral midazolam) in rapidly reducing depressive symptoms in adolescents with major depressive disorder at imminent risk for suicide.\u2026", "outcome_summary": null, "doi": "10.1176/appi.focus.26024113", "url": "https://pubmed.ncbi.nlm.nih.gov/42538892/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for adolescent depression and suicide risk.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "862fafff36b83c8ba7d9f412d27ce28d97bac56d2f4cb3577b80deba6df873ed", "title": "Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-04-01", "abstract": "Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatment choices with sustained efficacy and long-term tolerability.\u2026", "outcome_summary": null, "doi": "10.1176/appi.focus.26024111", "url": "https://pubmed.ncbi.nlm.nih.gov/42538888/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression (TRD).", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "f4ad35ee7d3c27cc9a29ff5384f8f7d95e9f376d50049646f9ee9292b8652c81", "title": "Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-04-01", "abstract": "Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S.\u2026", "outcome_summary": null, "doi": "10.1176/appi.focus.20250046", "url": "https://pubmed.ncbi.nlm.nih.gov/42538887/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for psychiatric disorders like depression and anxiety.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "425cd59216f620046795621cd0903c9c29efa597d86a47737d658ec9c73d0754", "title": "Use of Ketamine and Esketamine in the Pediatric Population: Current Evidence and Clinical Applications.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-04-01", "abstract": "Ketamine is a well-established anesthetic agent that is gaining increasing recognition for its diverse therapeutic applications, including the management of chronic pain, refractory status epilepticus, major depressive disorder, and suicidality.\u2026", "outcome_summary": null, "doi": "10.1176/appi.focus.20250040", "url": "https://pubmed.ncbi.nlm.nih.gov/42538882/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for depression, suicidality, and chronic pain in pediatrics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "e36876fd76d0fa0ca620809e5bfe7c6c2f5a98df47da121bfb753cc5103c0023", "title": "The Effect of Esketamine Combined with Pulsed Radiofrequency on Neuropathic Pain in Herpes Zoster Patients: A Randomised Clinical Trial.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-31", "abstract": "Zoster-related neuralgia (ZRN) remains challenging to treat with current analgesics and interventional therapies. Esketamine, an N-methyl-D-aspartate receptor antagonist, offers potent analgesic effects.\u2026", "outcome_summary": null, "doi": "10.1007/s40122-026-00868-1", "url": "https://pubmed.ncbi.nlm.nih.gov/42538490/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for chronic neuropathic pain in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "e484829fe772a7b539f665d9f830f232b26b61e700f6957c775d9a0cbdd855e4", "title": "A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-02-01", "abstract": "Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans, and the presence of multiple conditions requires innovative treatment approaches.\u2026", "outcome_summary": null, "doi": "10.3138/jmvfh-2025-0009", "url": "https://pubmed.ncbi.nlm.nih.gov/42534113/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for transdiagnostic psychiatric conditions in Veterans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "77b623f484a7e4ab62785ec7594bd2ff4e046dcee3be76b3da67a65abbeffbf7", "title": "A scoping review for published guidelines for use of ketamine in chronic non-cancer pain.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-07-30", "abstract": "Off-label ketamine infusions are often used to manage chronic non-cancer pain (CNCP), including neuropathic pain, central sensitisation and opioid dose reduction.\u2026", "outcome_summary": null, "doi": "10.1177/0310057X261460082", "url": "https://pubmed.ncbi.nlm.nih.gov/42533509/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for chronic non-cancer pain is a relevant therapeutic use.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "eb0e450baecb76ed6bb067530f16bda15262b8f51fa9c2a1960715c775a18cc5", "title": "Dissociation and antidepressant response to subcutaneous esketamine: A clinical study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-23", "abstract": "Ketamine and esketamine have reemerged as promising interventions for treatment-resistant depression (TRD), yet debate persists regarding the clinical relevance of acute dissociative experiences.\u2026", "outcome_summary": null, "doi": "10.1016/j.jpsychires.2026.07.016", "url": "https://pubmed.ncbi.nlm.nih.gov/42531622/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "f7f2aa09e1721f8d1de91783e1a168616c2448efe40fc66c89b985c5b0ae29f1", "title": "Pharmacological Influences on the R2 Blink Reflex Response in Healthy Participants: A Systematic Review.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-08-01", "abstract": "The R2 blink reflex (BR) is a polysynaptic brainstem-mediated response that can be activated by innocuous and noxious electrocutaneous stimulation of the supraorbital nerve and has been used as a biomarker across pharmacological studies.\u2026", "outcome_summary": null, "doi": "10.1111/ejn.70646", "url": "https://pubmed.ncbi.nlm.nih.gov/42530473/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Human study on pharmacological influences on a reflex response.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "ec6e6fd97468bb9945aa3c0291761d1daa648726042e92565943411856f592be", "title": "Treatment-resistant Depression in the Post-ketamine Era: Unmet Needs beyond Rapid Response.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-08-31", "abstract": "The introduction of ketamine and its S-enantiomer, esketamine, has been one of the most consequential advances in treatment-resistant depression (TRD) in recent decades, demonstrating that rapid and clinically meaningful antidepressant effects can occur within hours, even in patients who have not responded to conventional treatments.\u2026", "outcome_summary": null, "doi": "10.9758/cpn.26.1487", "url": "https://pubmed.ncbi.nlm.nih.gov/42528339/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "b02ded9d52d4ed765ce2f0df6a6072b3745a57d0177bd8a6610379aa4a410918", "title": "Dimensional effect profiles in treatment-resistant depression: A naturalistic, prospective head-to-head comparison of arTMS, esketamine nasal spray, and oral brexpiprazole.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-28", "abstract": "Treatment-resistant depression (TRD) is a heterogeneous condition in which symptoms such as anhedonia, rumination, and anxiety contribute to persistent disability.\u2026", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122333", "url": "https://pubmed.ncbi.nlm.nih.gov/42521097/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Compares esketamine nasal spray for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "ff30d4e9351225fa807beff207d2858dc54e67981e6eb8cc22f8536589f205da", "title": "Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.", "compound": "ketamine", "type": "meta_analysis", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-28", "abstract": "Anxiety symptoms are common in patients with major depressive disorder (MDD). The presence of anxiety symptoms can indicate greater depression severity, and is associated with a higher comorbidity burden, suicidality, lower levels of functioning, and poorer quality of life.\u2026", "outcome_summary": null, "doi": "10.1007/s40263-026-01315-7", "url": "https://pubmed.ncbi.nlm.nih.gov/42518156/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "MDD with anxiety is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "0ed35bbf38820ec3fc4a8cc2b6bfc0eb9c5e2b18531525ca21e478fa5d7f910c", "title": "Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-28", "abstract": "Ketamine and esketamine are increasingly used for treatment-resistant depression (TRD), yet their hepatic safety profile with repeated or long-term use remains poorly characterized.\u2026", "outcome_summary": null, "doi": "10.1097/JCP.0000000000002228", "url": "https://pubmed.ncbi.nlm.nih.gov/42517206/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Hepatic safety of ketamine/esketamine for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "91ce0a9c4d06bee84c826d98be7140f64fe5a7c94b14621ee62513141adaefec", "title": "Esketamine in Treatment-Resistant Depression: Clinical and Translational Perspectives.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-22", "abstract": "Esketamine, an intranasally administered N-methyl-D-aspartate (NMDA) receptor antagonist, represents a significant advancement in the treatment of Major Depressive Disorder (MDD), particularly among patients with Treatment-Resistant Depression (TRD).\u2026", "outcome_summary": null, "doi": "10.2174/011570159X465328260703100233", "url": "https://pubmed.ncbi.nlm.nih.gov/42515873/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "09b807b9ad5f184cec7808822f06bdab40fd81c8b982800f91d0453353bf9097", "title": "The functional role of ERK activity in esketamine's antidepressant effects.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-26", "abstract": "Esketamine has been approved for the treatment of treatment-resistant depression. However, there is an unmet clinical need to extend the duration of esketamine's action to reduce the high recurrence rate after drug withdrawal and the potential side effects of repeated esketamine use.\u2026", "outcome_summary": null, "doi": "10.1016/j.pbb.2026.174248", "url": "https://pubmed.ncbi.nlm.nih.gov/42503396/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "c6fccedb0c7a5508bf3d60028efd931543ecd3e55be803a8436b19bf123e512a", "title": "Rapid clinical and EEG microstate changes 24\u00a0h after intranasal esketamine in major depressive disorder with suicidal ideation: a prospective paired study.", "compound": "ketamine", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": null, "status": "published", "date": "2026-07-23", "abstract": "Major depressive disorder (MDD) with suicidal ideation constitutes a psychiatric emergency that requires rapid symptom relief. Intranasal esketamine can reduce depressive symptoms within hours, yet the earliest brain-level correlates of response remain insufficiently characterized.\u2026", "outcome_summary": null, "doi": "10.1016/j.jad.2026.122307", "url": "https://pubmed.ncbi.nlm.nih.gov/42492692/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for major depressive disorder with suicidal ideation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "0fb8ef77fcc0b8135df81463333a1954687c0f4910e08958e97933ec72f36f91", "title": "The UTHealth Ketamine Project", "compound": "ketamine", "type": "phase_2", "institution": "The University of Texas Health Science Center, Houston", "condition": "depression", "sample_size": 10, "status": "completed", "date": "2016-11-07", "abstract": "The primary objective of this study is to determine the effectiveness of serial infusions of intravenous (IV) ketamine in adults with treatment resistant depression (TRD).", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02882711", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for treatment resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "2346837c943c40f2fd814b259f098f9987b05ab49b85a1abf441927a3010e2a7", "title": "Esketamine as Treatment for Chronic Pain Due to Endometriosis: a RCT Study", "compound": "ketamine", "type": "phase_3", "institution": "Reinier de Graaf Groep", "condition": "other", "sample_size": 56, "status": "recruiting", "date": "2024-03-01", "abstract": "The goal of this randomized controlled trial is to investigate the effect of esketamine versus placebo on the NRS score for chronic pelvic pain. Secondary endpoints are to assess pain scores, side-effects, quality of life, depressive symptoms and pain coping.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06161805", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for chronic pain and associated symptoms in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "e7a4eafc91df9f6723006bdfebddf268230358bf2ed3b6c1d0c5943e3150c884", "title": "Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment", "compound": "ketamine", "type": "observational", "institution": "Yale University", "condition": "depression", "sample_size": 7, "status": "completed", "date": "2024-07-11", "abstract": "Investigators aim to examine the role of audiovisual inputs during treatment with ketamine/esketamine in affecting tolerability and effectiveness of treatment of depressive episodes, by providing patients with a relaxing environment using virtual reality goggles and noise cancelling headphones, and assessing whether these tools can improve the tolerability and effectiveness of treatment with ketamine/esketamine", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06139016", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine/esketamine for depressive episodes with VR adjunct.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "5e13d44e2f61a64621b5548bcd29cb78effafbe6125d795d9cd371585cbe2a23", "title": "Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression", "compound": "ketamine", "type": "phase_2", "institution": "Celon Pharma SA", "condition": "depression", "sample_size": 88, "status": "completed", "date": "2019-02-25", "abstract": "The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03965858", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for treatment-resistant depression in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "136eccd2ec4d8aa0d0e6790e0d1b28a54109a26340d59e455a5cdef704b6fef1", "title": "Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression", "compound": "ketamine", "type": "phase_2", "institution": "VA Office of Research and Development", "condition": "depression", "sample_size": 62, "status": "completed", "date": "2015-04-01", "abstract": "About one-third of depressed patients will not get better after multiple antidepressant treatments. This situation put a high burden on patients with depression due to worsening quality of life and increasing health care costs.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02360280", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression is a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "dc261fa4e07292808112c8cabaa8b372829e6caa9671674437f83dfc0e6582c3", "title": "Ketamine For Suicidal Ideation", "compound": "ketamine", "type": "observational", "institution": "James Murrough", "condition": "other", "sample_size": 24, "status": "completed", "date": "2012-01-01", "abstract": "This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01507181", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for suicidal ideation in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "097ef04823db2052e7000bee627fe98ed94b3b5f6ed706170fdd9004f7567c7f", "title": "Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease", "compound": "ketamine", "type": "phase_1", "institution": "University of Arizona", "condition": "other", "sample_size": 9, "status": "active", "date": "2019-07-28", "abstract": "The primary objective is to determine the tolerability and efficacy of a low-dose ketamine infusion for the treatment of Levodopa-Induced dyskinesias (LID), both acutely and during post-infusion evaluation (week 2-6), as measured by a change in patient diaries of dyskinesia and the UDysRS.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06021756", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for chronic pain/movement disorder in Parkinson's", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "1733d9111de2d6994b57c5935adfbf512a4937bfe1e0850900b881536f63cea3", "title": "The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects", "compound": "ketamine", "type": "observational", "institution": "Yale University", "condition": "other", "sample_size": 16, "status": "completed", "date": "2008-08-01", "abstract": "The purpose of the study is 1. To establish the feasibility of fMRI studies of the interaction of guanfacine and ketamine. 2. To explore the possibility that guanfacine can ameliorate the negative effects of ketamine on task-related prefrontal activation. 3.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT01600885", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Human study on ketamine's effects on working memory.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "2f2f91ef67008c7520aa7518a8651fe5d5e79bad995165acddbad36de4138604", "title": "Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain", "compound": "ketamine", "type": "phase_2", "institution": "Hospital de Clinicas de Porto Alegre", "condition": "other", "sample_size": 24, "status": "completed", "date": "2017-01-02", "abstract": "This is a clinical trial that intend to determine the effects of S-ketamine on event-related potentials associated with semantic affective pain-processing", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03915938", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine used to treat chronic pain, human study.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "36fe0bccf7e416a3f27493efa49f72b7521b772e3adaf0ee259b5cb6eff3517a", "title": "Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression", "compound": "ketamine", "type": "observational", "institution": "Taipei Veterans General Hospital, Taiwan", "condition": "depression", "sample_size": 12, "status": "completed", "date": "2022-03-15", "abstract": "In the past decades, the prevalence of adolescent depression and suicide increased significantly in Taiwan and worldwide. To date, the suicide mortality is the second mortality cause in the adolescent and young adult population in Taiwan.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT05045378", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Low-dose ketamine for treatment-resistant depression in adolescents.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "1034b1dd3a156f420c6d29b3a3080f441b1cf00c812699800e58b1cd1dd6114d", "title": "Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder", "compound": "ketamine", "type": "phase_2", "institution": "Pouya Movahed Rad", "condition": "depression", "sample_size": 198, "status": "completed", "date": "2015-02-01", "abstract": "Developing more effective and faster acting antidepressant is of outmost clinical importance. Available antidepressant therapies have a delayed therapeutic effect. It typically takes several weeks before symptom relief is evident.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02659085", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for major depressive disorder, comparing to ECT.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "411f080234c4262c553eee353cded043c145f7f5e93eab61160249671432130f", "title": "54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide", "compound": "ketamine", "type": "phase_3", "institution": "Janssen Research & Development, LLC", "condition": "depression", "sample_size": 230, "status": "completed", "date": "2017-06-15", "abstract": "The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT03097133", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for major depressive disorder with suicidal ideation.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "afa2a5e2dc3d5d77f4d0adff987db93cd0723ae10631c467065eb4d2b7fa2da8", "title": "Effectiveness of Ketamine Administered by Mesotherapy in Complex Regional Pain Syndrome Type 1 (CRPS1)", "compound": "ketamine", "type": "phase_2", "institution": "Hospices Civils de Lyon", "condition": "other", "sample_size": 31, "status": "completed", "date": "2021-11-05", "abstract": "Complex Regional Pain Syndrome type 1 (CRPS1) is a disabling pain syndrome. Its definitive treatment has not been established and the results of current treatments are often unsatisfactory. The prognosis is difficult to establish because the vast majority of CRPS regresses within a few weeks.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04650074", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for chronic pain (CRPS1) in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "528fc75dfc1ca646c9f94f7b45a20eb69383921e2aa3194b31c41c815b50eb12", "title": "Reverse Engineering Ketamine\u2019s Effects May Lead to New Antidepressants", "compound": "ketamine", "type": "news", "institution": "Weill Cornell Medicine", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-05-01", "abstract": "Weill Cornell Medicine Care Discover Teach # Reverse Engineering Ketamine\u2019s Effects May Lead to New Antidepressants May 1, 2026 Share to Facebook Share to Twitter Share to LinkedIn Share on Email silhouette of a woman with her head in her hand Credit: Shutterstock Weill Cornell Medicine investigators have \u201creverse engineered\u201d ketamine\u2019s antidepressant effects to identify potential new strategies for treating depression.\u2026", "outcome_summary": "Weill Cornell Medicine investigators have \"reverse engineered\" ketamine\u2019s antidepressant effects to identify potential new strategies for treating depression. Ketamine can provide immediate relief to some patients with treatment-resistant depression, but the effects are often short-lived and it has serious side effects.", "doi": null, "url": "https://news.weill.cornell.edu/news/2026/05/reverse-engineering-ketamine%E2%80%99s-effects-may-lead-to-new-antidepressants", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Investigational treatment for treatment-resistant depression.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "c15402bd273b3463e96a1988665ac381b26b9c8b64f1b2f11b30f59bb02fc38d", "title": "Structural imaging predictors of ketamine response in treatment-resistant depression: a machine learning approach", "compound": "ketamine", "type": "phase_3", "institution": null, "condition": "depression", "sample_size": 99, "status": "published", "date": "2026-05-12", "abstract": "Reprints and permissions ## About this article Check for updates. Verify currency and authenticity via CrossMark ### Cite this article Bryant, L., Alexander, L., Mena, S. et al. Structural imaging predictors of ketamine response in treatment-resistant depression: a machine learning approach.\u2026", "outcome_summary": "A machine-learning model using pre-treatment structural MRI data predicted antidepressant response to ketamine in adults with treatment-resistant depression with a balanced accuracy of 72.2% in the discovery sample and 60.0% in external validation. Greater gray matter volume in frontal regions predicted response, while greater cerebellar volume predicted non-response.", "doi": "10.1038/s41398-026-04085-4", "url": "https://www.nature.com/articles/s41398-026-04085-4", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for treatment-resistant depression, human study", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "f4912fb460200c442d5ca7f7cd1c32aceac98b0139d8a7b5f920b26206c4748e", "title": "Advancing the Treatment of Depression", "compound": "ketamine", "type": "meta_analysis", "institution": "UConn School of Medicine", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-05-06", "abstract": "The researchers analyzed 26 existing randomized controlled trial studies that compared intravenous ketamine with controls. They found that ketamine was more effective than a placebo over the short term of a few days, but the effects were less pronounced after a few weeks.\u2026", "outcome_summary": "Two studies evaluated existing drugs used in new ways to treat major depression. One found intravenous ketamine was more effective than placebo in the short term for depression and rapidly reduced suicidal impulses. The other meta-analysis found some antipsychotics were more likely to decrease depression symptoms, but the most effective one, lumapeterone, also had the most side effects.", "doi": null, "url": "https://today.uconn.edu/2026/05/advancing-the-treatment-of-depression", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Intravenous ketamine for depression and suicidal impulses.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "0747b2e3b03f4202ce702c832bfc84820e71e49ca1c5c73736141117e1fc8a55", "title": "Is Ketamine for Depression Moving Too Fast on Weak Data?", "compound": "ketamine", "type": "observational", "institution": "Trinity College Dublin", "condition": "depression", "sample_size": null, "status": "published", "date": "2026-05-15", "abstract": "\u201cThe Trinity study clearly demonstrated that the addition of ketamine repeated injections was no better in reducing depressive symptoms than repeated placebo injections, both added to standard antidepressant treatment.\u2026", "outcome_summary": "A study investigating racemic ketamine infusions for depression found no additional benefit compared to a placebo when added to usual inpatient care, leading researchers to question if ketamine's efficacy for depression has been overstated.", "doi": "10.1001/jamapsychiatry.2024.0500", "url": "https://www.medscape.com/viewarticle/ketamine-depression-moving-too-fast-weak-data-2026a1000fr0", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine for depression, human study, efficacy questioned.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "a9ce6a7ec84afdf7b27aa7604c5b09adee0d94358ff19f9a5dd57a296f6df659", "title": "Ketamine: How Yale Redefined Depression Treatment", "compound": "ketamine", "type": "news", "institution": "Yale", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-02-24", "abstract": "The results of studies on esketamine were remarkable. Clinical trials showed that esketamine was effective even for patients who had not responded to multiple prior treatments.\u2026", "outcome_summary": "Yale researchers have been instrumental in redefining depression treatment through their work with ketamine, exploring its rapid antidepressant effects and mechanisms.", "doi": null, "url": "https://medicine.yale.edu/news-article/ketamine-how-yale-redefined-depression-treatment", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine used for depression treatment in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "32a51580bd38d6e4248deebc4ca956da00da9e08015b20ca3932b4f83f51793f", "title": "Ketamine Therapy", "compound": "ketamine", "type": "news", "institution": "Cleveland Clinic", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-01-16", "abstract": "Rare side effects may include: Researchers are still studying the long-term safety of ketamine for depression and other mental health conditions. Because of this, there may be long-term effects that aren\u2019t yet fully known. ## Recovery and Outlook ### How long do I need ketamine therapy?\u2026", "outcome_summary": "Ketamine therapy uses a low dose of an anesthetic to treat depression, anxiety and some chronic pain by blocking certain brain signals and helping nerve cells form new connections, potentially improving mood quickly. Treatment is given by IV or nasal spray under medical supervision and may require multiple sessions.", "doi": null, "url": "https://my.clevelandclinic.org/health/treatments/ketamine-therapy", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ketamine therapy for depression, anxiety, and chronic pain.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } } ], "lsd": [ { "id": "80e028e9587252efd6f5e42d6856083775ee59842c5f3e1fe50e9c2aee2acfbd", "title": "Neuronal Correlates of Altered States of Consciousness", "compound": "lsd", "type": "observational", "institution": "University Hospital, Basel, Switzerland", "condition": "other", "sample_size": 24, "status": "completed", "date": "2014-12-01", "abstract": "The aim of the present study is to assess the neuronal correlates of alterations in waking consciousness pharmacologically induced by a 5-hydroxytryptamine (HT)2A receptor agonist in healthy subjects using functional magnetic resonance imaging (fMRI).", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT02308969", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "fMRI study of 5-HT2A agonist in healthy subjects", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } } ], "dmt": [ { "id": "b1decb0406b21ca4e726166d589d18fc0a42337b9dfba47ca8f03dfe29d380b8", "title": "Safety of GH001 in Healthy Volunteers", "compound": "dmt", "type": "phase_1", "institution": "GH Research Ireland Limited", "condition": "other", "sample_size": 22, "status": "completed", "date": "2019-03-13", "abstract": "The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and its dose-related psychoactive effects in healthy volunteers.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT04640831", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Safety and psychoactive effects of 5-MeO-DMT in healthy volunteers.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "28b245c29ab7e29266a79a6adc0632d059fa23ef9ed06c319a7be445ab32a6f4", "title": "Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects", "compound": "dmt", "type": "phase_1", "institution": "GH Research Ireland Limited", "condition": "other", "sample_size": 52, "status": "recruiting", "date": "2024-08-01", "abstract": "The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration and a single-day individualized dosing regimen (IDR).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT06511947", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Human pharmacokinetics and safety study of a novel compound.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "89e051c19bcaed29ed4acb8cf2c77156aabe379e913c7cb5abc82ad72a84ea8d", "title": "A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial", "compound": "dmt", "type": "phase_2", "institution": null, "condition": "depression", "sample_size": 34, "status": "published", "date": "2026-02-01", "abstract": "This was a phase IIa double-blind, placebo-controlled, randomized clinical trial. The sponsor, Small Pharma (now Cybin UK), designed and supported the trial and provided a proprietary pharmaceutical-grade formulation of DMT fumarate (SPL026), which was analyzed for stability and purity.\u2026", "outcome_summary": "A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to 3 months. The treatment was well-tolerated and safe.", "doi": "10.1038/s41591-025-04154-z", "url": "https://www.nature.com/articles/s41591-025-04154-z", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psychedelic treatment for major depressive disorder in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } } ], "ibogaine": [ { "id": "e01c01a095f66497f9f6e7d843e295e4fc486870ea1dfb3bd5f75e2db3054cb7", "title": "Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study.", "compound": "ibogaine", "type": "phase_2", "institution": null, "condition": "anxiety", "sample_size": null, "status": "published", "date": "2026-07-28", "abstract": "Ibogaine is a natural hallucinogen with emerging evidence for treating substance use disorders. However, its cardiovascular effects are not fully known, and most clinical data focus on opioid dependence, with limited data for Alcohol Use Disorder (AUD).\u2026", "outcome_summary": null, "doi": "10.47626/2237-6089-2026-1437", "url": "https://pubmed.ncbi.nlm.nih.gov/42520175/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Ibogaine for alcohol use disorder, a psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } } ], "other": [ { "id": "6b7a32bd2aa3f95fef7bb45e91832d1db5da8ff61f5f0252fe56cffa961479aa", "title": "\"I've Done My Research\": Psychedelics, PTSD, and the Therapeutic Alliance.", "compound": "other", "type": "phase_2", "institution": null, "condition": "PTSD", "sample_size": null, "status": "published", "date": "2026-04-01", "abstract": null, "outcome_summary": null, "doi": "10.1176/appi.focus.20260003", "url": "https://pubmed.ncbi.nlm.nih.gov/42538891/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Psychedelics and PTSD are a relevant psychiatric indication.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "5eb461d9def9976574cf4720bdf2571fa2aae0a6dbb4b4c65d4df63bc3382b7b", "title": "Conceptual analysis of mechanisms and methods in psychedelic clinical trial design: a narrative review.", "compound": "other", "type": "meta_analysis", "institution": null, "condition": "other", "sample_size": null, "status": "published", "date": "2026-01-01", "abstract": "Clinical trials with psychedelics face several challenges that are not present to such a degree with other pharmacotherapeutics.\u2026", "outcome_summary": null, "doi": "10.1177/20451253261470523", "url": "https://pubmed.ncbi.nlm.nih.gov/42504298/", "source": "PubMed", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Review of clinical trial design for psychedelic therapeutics.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "f61706e9f76828f1c40e0ae461f850479a937481325a10c2f4d0880c145c84bb", "title": "The NeXT Study; The Netherlands XTC Toxicity Study", "compound": "other", "type": "observational", "institution": "UMC Utrecht", "condition": "other", "sample_size": 225, "status": "completed", "date": "2002-04-01", "abstract": "The purpose of this study is to investigate the possible neurotoxic effects of the party-drug Ecstasy (MDMA)on brain and brain function in humans. Main research questions concern the causality, course and clinical relevance of the neurotoxicity of ecstasy", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT00235768", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Investigates neurotoxic effects of MDMA in humans.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "ee51cbf1df09b2806971b2d9b0bd6fdf43cbffbe89f3c475b5d064df99cda63a", "title": "Functional Brain Imaging in Recreational Users of Ecstasy", "compound": "other", "type": "observational", "institution": "Hadassah Medical Organization", "condition": "other", "sample_size": 18, "status": "completed", "date": "2006-01-01", "abstract": "Recreational use of \"ecstasy\" (MDMA; 3,4-methylenedioxymethamphetamine) is associated with long-lasting effects on metabolism in the human brain.\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT00254306", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Observational study of human recreational MDMA use", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "e544b1e3a296ff9954f7a232dc7a0569589b44f30e9c77cd2795bb0d53981c3d", "title": "Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive Disorder", "compound": "other", "type": "observational", "institution": "Shanghai Mental Health Center", "condition": "depression", "sample_size": 130, "status": "recruiting", "date": "2026-05-30", "abstract": "This study focuses on the neurobiological changes in MDD patients with high suicidal risk during rapid antidepressant treatments, such as Esketamine and Electroconvulsive Therapy (ECT).\u2026", "outcome_summary": null, "doi": null, "url": "https://clinicaltrials.gov/study/NCT07602153", "source": "ClinicalTrials.gov", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "Esketamine for major depressive disorder with suicidal risk.", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } }, { "id": "ec4f82b3085e633d80edc915c9578eb8ef692773a5286296ac17abf3de9caddc", "title": "Final psychedelics guidance suggests FDA is \u2018receptive\u2019 to helping companies succeed", "compound": "other", "type": "regulatory", "institution": "FDA", "condition": "depression", "sample_size": null, "status": "other", "date": "2026-07-14", "abstract": "# Final psychedelics guidance suggests FDA is \u2018receptive\u2019 to helping companies succeed.\u2026", "outcome_summary": "The FDA released final guidance for developers of psychedelic drugs, updating its 2023 draft recommendations and providing a framework for future regulatory action. This guidance suggests the agency is receptive to helping sponsors succeed in developing these compounds for mental health.", "doi": null, "url": "https://www.biospace.com/fda/final-psychedelics-guidance-suggests-fda-is-receptive-to-helping-companies-succeed", "source": "General News", "first_seen": "2026-08-03", "relevance": { "relevant": true, "reason": "FDA guidance on psychedelics for mental health", "model": "google/gemini-2.5-flash-lite", "revision": 2, "judged": "2026-08-03" } } ] } }